Cargando…
Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability
BACKGROUND: Oral glucocorticoids (GCs) have been shown to be effective in reducing the inflammatory symptoms of rheumatoid arthritis, but their use is not supported by evidence in spondyloarthritis (SpA). Modified-release (MR) oral prednisone taken at bedtime has been shown to be more effective than...
Autores principales: | Bandinelli, Francesca, Scazzariello, Francesco, Pimenta da Fonseca, Emanuela, Barreto Santiago, Mittermayer, Marcassa, Claudio, Nacci, Francesca, Matucci Cerinic, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115695/ https://www.ncbi.nlm.nih.gov/pubmed/27881910 http://dx.doi.org/10.2147/DDDT.S115099 |
Ejemplares similares
-
IgG4-Related Disease: A Multispecialty Condition
por: Usêda Santana, Iuri, et al.
Publicado: (2014) -
Effectiveness of SB4 Transition from Originator Etanercept in Rheumatoid Arthritis and Axial Spondyloarthritis: A Subgroup Analysis from the BENEFIT Study
por: Luciano, Nicoletta, et al.
Publicado: (2022) -
Etanercept in axial spondyloarthritis
por: Luo, Gui, et al.
Publicado: (2022) -
The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology
por: Malaviya, Anand N., et al.
Publicado: (2017) -
Cytokine profiles in axial spondyloarthritis
por: Madej, Marta, et al.
Publicado: (2015)